Randomized Trialvery high evidence
Sibeprenlimab in IgA Nephropathy - Final Phase 3 Trial Analysis.
The New England journal of medicine·October 22, 2026·PMID 42911185
Why it mattersIgA nephropathy often progresses to kidney failure despite current therapies. Sibeprenlimab, by inhibiting APRIL, targets a key pathogenic pathway and demonstrated substantial preservation of kidney function, offering a potential disease-modifying option for patients at risk of progression.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled